You are here

Dolutegravir (Tivicay): A Next Generation Integrase Inhibitor

Note: This is an archived resource. It is provided here for general reference, but users are advised to refer to other sources to confirm information. See full site Disclaimer.

This presentation focuses on Dolutegravir,  the latest antiretroviral drug to be approved by the FDA. This is an advanced training intended for physicians, nurse practitioners, physician assistants, and other healthcare professionals providing medical care to HIV-infected individuals.

Add comment

Log in to post comments